Versamune ® is a registered trademark of PDS Biotechnology Corporation. Investor Contact: Mike Moyer LifeSci Advisors Phone +1 (617) 308-4306 Email: mmoyer@lifesciadvisors.com ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs.

Asthma inhalers are one type of allergic asthma medication that can help when symptoms begin. Find out which other types of ...

A key differentiator of this vaccine is its ability to target the entire viral genome, much like the Company’s lead product candidate, TVGN 489. This strategy helps mitigate the risk posed by ...

The United Kingdom has launched the world’s first clinical trial for a personalised cancer vaccine. Unlike traditional ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS ...

The following is a summary of "Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines," ...

Researchers have discovered a new approach to prostate cancer treatment by combining immunotherapy with PIM1 kinase ...

Antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic agents, offer a targeted approach to cancer therapy, aiming to deliver ...

An experimental treatment for an aggressive and lethal brain cancer has been published in Nature Medicine, paving the way for ...